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Abstract 
 
Our aim was to evaluate, in a remote Aboriginal community with high rates of renal and 
cardiovascular disease, whether episodes of acute post-streptococcal glomerulonephritis (PSGN) 
increase risk for chronic kidney disease in later life.  Subjects were community members who 
participated in a health screen from 2004-2006.  Albumin/creatinine ratios (ACRs) were measured on 
random urine samples and medical records were reviewed for histories of episodes of acute PSGN.   
1519 people participated in the screen, or about >85% of those age-eligible. High levels of 
albuminuria and increases with age were confirmed.  200 people had had episodes of PSGN, 27 
people on more than one occasion, usually in childhood. All episodes were associated with group A 
streptococcal skin infections, often associated with scabies.  Of people ages 10 to 39 yr at screening, 
18.4% of males and 21.6% of females had such a history. Among them, a history of “remote” PSGN 
(>5 years earlier) was associated with higher levels of ACR than in those without, p<0.0001 for 
females and p<0.0001 for males. Furthermore, in females age 30-39 years, a PSGN history was 
associated with a higher frequency of estimated glomerular filtration rate <60 ml/min (14% vs 0%,  
p=0.0003). The adjusted odds ratios (CI) for ACR >34 gm/mol (300 mg/gm, or overt albuminuria) in 
males and females with a remote history of PSGN, when compared with those without such a history, 
were 4.6 (1.9-11.1) and 3.1 (1.5-6.3) respectively. We conclude that PSGN is contributing to the very 
serious burden of CKD in this community.  Rigorous strategies to prevent scabies and Group A 
streptococcal infections will reduce the burden of kidney disease.    
. 
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Introduction 
 
Although now unusual in western countries and in Australia in general,(1) post-streptococcal 
glomerulonephritis (PSGN) is still common in Australia Aboriginal children living in remote 
communities, (2-5)  where scabies is common and group A streptococcal pyoderma is endemic. 
PSGN occurs in both sporadic and epidemic forms. In these communities, chronic renal disease and 
end-stage renal failure also occur in adults at alarming rates.(6,7)   
 
PSGN is usually followed by clinical recovery over several days to weeks, and the long-term outlook 
has generally been regarded as excellent, with no increase in risk of urinary abnormalities or 
hypertension.(8-10) However, some studies have suggested that there is an increase in chronic renal 
impairment after this illness.(11,12)  
 
In one high risk Aboriginal community we described persisting urine abnormalities among 62 children 
who had symptomatic PSGN during specific epidemics in the 1980s,(4) and higher rates of 
microalbuminuria in people with a clinical history of PSGN at ages 15-29 years.(13) We now evaluate 
in that same community, the association of documented episodes of PSGN with albuminuria during a 
second community-wide conducted from 2004-2006, or more than 10 years later. 
 
Results. 
 
1519 people participated in the screening program, or about 85% of the age-eligible population.  Of 
these, 200 had a history of PSGN recorded in their clinic charts: 173 had a single episode, and 27 
had two or more episodes. Figure 1 shows the timing of those episodes, all of which had been 
documented since 1970. There were major epidemics in the early 1980s and in 1987, and smaller 
epidemics in 1994, 1999/2000 and in 2005, as well as substantial numbers of endemic cases 
throughout. There is limited information on streptococcal serotypes prior to the year 2000, but many 
cases were emm55 by anecdotal recall. In the year 2000 recorded serotypes in cases included 
emm49.4, emm95 and emm86, in 2001 one case was emm1105, and in 2005 cases were mostly 
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emm55 (Catherine Marshall and Bart Currie, Menzies School of Health Research, personal 
communication). Table 1 shows the numbers and proportions of people by sex and age group who 
had such a history. In all, 16.5% (n=92) of males and 19% of females (n=85) aged 5-39 years had 
a documented history of PSGN.  Rates in people age >40 years at screening were lower than in 
younger people, and as noted above, they are excluded from further analyses.   
 
Participants were then restricted to those age 10-39 years at examination, with ACR values available 
on the community screen. Those without a PSGN history were compared with those with a PSGN 
history recorded >5 years prior to the examination.  These constituted 969 persons, of whom 177 
(18.7%) had a PSGN history, >5 years earlier - 16.5% of males and 20.7% of females, as shown in 
Table 2.   The table also shows that the PSGN episodes had usually occurred in childhood. The 
average time since the episodes for those age 20-29 years at screening was about 18 yr, and for 
those who were 30-39 yr olds at screening it was 25 yr.   
 
Table 3 compares some characteristics of those without and with a remote history of PSGN 
and those with on history of PSGN. Those with a PSGN history were somewhat older, on 
average, compatible with the major epidemics in the 1980s. There were no significant 
differences between the groups in BMI, blood pressure, CRP or lipid levels (apart from a lower 
LDL level in males with a PSGN history). Those with PSGN tended towards higher rates of 
diabetes than those without; however, this was not significant with adjustment for age, and 
HBA1c levels were not different. Among the “renal” indicators, average serum creatinine 
levels were higher in females with a remote history of PSGN than those without. In addition, 
people with a PSGN history tended towards higher rates of hematuria, had significantly higher 
rates of proteinuria by dipstick, had higher mean ACR levels and were more likely to have 
“elevated” levels of ACR by category than those without a PSGN history. It is noteworthy that 
most individuals with high ACR levels (> 34 mg/mmol) also had proteinuria, ie. 81% of males 
and 93% of females,  with p<0.0001 for the association between the two in both sexes.   
Table 4 shows trends towards higher ACRs in those with a remote PSGN history in all age 
groups and in both sexes.   There were no differences in e-GFR according to PSGN history in 
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any age group in males, and none had e-GFR <60.  However, in females age 30-39 years there 
was a trend towards lower eGFRs in those with a PSGN history, and 12% of that group had 
“low” GFR levels, which was significantly higher than the 0% in those without such a history 
(p=0.0003).   
Figure 2 compares the distribution of ACR according to a remote PSGN history in both males 
and females. In all groups those with PSGN had a broader distribution of ACR values than 
those without, and the mean values were notably higher in those with PSGN in the two older 
age groups. Figure 3  also demonstrates the higher average values of ACR in the PSGN 
groups.  Figure 4 shows that trends to higher categories of ACR in those with PSGN are 
apparent in both sexes across all age groups.    
Table 5 summarizes the risk exacerbations for albuminuria above the microalbuminuia 
threshold ACR >3.4), and above the overt albuminuria threshold (ACR >34) according to a 
remote history of PSGN, adjusted for age.  A history of PSGN was associated with an almost 3-
fold increase in rates of ACR >3.4  and a >3-fold increase in overt albuminuria in males, and 
with more than 2-fold increases of each in females.  The strength of these associations was 
unchanged or strengthened with adjustment for BMI, blood pressure and diabetes.  
 
Among people who were 20-39 years old at screening, neither the time since the PSGN episode nor 
the age at the PSGN episode were significant determinants of renal function at screening. 
 
Discussion 
 
Documented episodes of PSGN, both epidemic and sporadic, have been very common since 1970 in 
this Aboriginal group.  In the mid 2000s, about 15% of adolescents (10-19 yr) and more than 20% of 
young adults (20-39 yr) had such a history recorded, with females equally or more often affected than 
males.  In both sexes, those with a history of PSGN 5 or more years earlier, in whom acute 
inflammatory effects of PSGN should have subsided, had higher average levels of ACR than those 
without such a history, and were 3 to 4 times more likely to have elevated levels of ACR at the 
microalbuminuria and the overt albuminuria cutoffs.  They also tended towards higher rates of 
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proteinuria, and hematuria by dipstick.  In addition, 12% of females age 30-39 yr with a remote PSGN 
history had low levels of e-GFR by the standard definition.     
 
Thus PSGN contributes to the burden of CKD in this community. In view of the powerful predictive 
value of baseline levels of albuminuria for CKD progression and for both nonrenal and renal 
deaths,(14,15) it must also contribute to this community’s high rates of renal failure and premature 
nonrenal mortality.  
  
The findings are consistent with the higher prevalence of microalbuminuria documented more than 10 
years earlier in the same community in people age 15-29 years with a recorded PSGN history.(13)  
They are also compatible with a case-control study showing high levels of albuminuria in children who 
had had PSGN during the 1980s epidemics.(4)  The current study adds value in the embrace of all 
recorded episodes of GN between 1970 and 2005; in the greater number of people with PSGN 
examined, specification of a 5+ yr interval to define delayed sequelae of PSGN, and the more 
advanced age (>10 years greater) of the older participants.  In an environment where ACR levels 
increase with age,(13)  the progression into adult life of people who had episodes of PSGN in 
childhood allows more fulsome expression of its renal damaging effects. It particularly illuminated the 
association of a remote history of PSGN with higher rates of overt albuminuria, whose role as a 
marker of kidney disease and predictor of renal and nonrenal death is now incontrovertible.(13-15)  
The demonstration of lower GFRs in some subjects with a PSGN history, specifically females age 
30-39 yr, is also new.   
 
Thus our knowledge of long term sequelae of PSGN is expanded.(1,8-12,16-21) Demonstration in 
other settings of a reduced renal functional reserve supports such an association.(22,23) The data 
suggest that, in some people, kidney damage persists or is superimposed years after the acute PSGN 
episodes.  Persisting or secondary inflammation, as well as hyperperfusion or hypertrophy of 
remaining nephrons/glomeruli following loss of a critical number of nephrons could both be among the 
mechanisms.(24)  Kidney biopsy data in this and other remote Aboriginal settings are supportive, 
showing high rates of post-infectious GN and glomerulomegaly which presumably marks 
compensatory hypertrophy.(25,26) 
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Strengths of this study include the excellent ascertainment in the screen, the availability of the clinical 
records, the sweep of the historical information over 35 years, and the detailed knowledge of the 
distribution, associations and natural history of renal disease in this community.(13-15) The striking 
frequency of PSGN, and the high density of other nephropathic factors in this environment have 
probably helped educe the phenomenon.  Weaknesses include the variable sensitivity to PSGN 
episodes over time, and failure to detect some cases of PSGN have probably resulted in 
underascertainment of its contribution to CKD.  In hindsight, health workers comment that, in non-
epidemic years and in the lead up to recognized epidemics, a child appearing “puffy” has sometimes 
not been further evaluated.  In these settings, too, asymptomatic cases are entirely missed, although 
heightened consciousness and some targeted screening precipitated by symptomatic cases heralding 
epidemics result in more case-finding at those times. Undiagnosed cases probably contribute to some 
of the “unexplained” albuminuria in community members without a recognized PSGN history.  
However, asymptomatic episodes are likely to be associated with a less serious acute course, as well 
as less marked long term consequences through lower levels of permanent nephron loss.  
 
The data support the inclusion of PSGN as one vital factor in the multideterminant model of 
albuminuria. Such a model was first formulated in this community,(13) and is conceptually supported 
by the “multihit” hypothesis of renal disease later proposed by Nenoff and colleagues.(27)  Other 
factors whose significant association with albuminuria we have modeled include age, lower 
birthweights, skin sores and scabies, non-skin infections (specifically with H. pylori), high CRP levels, 
levels of glycemia, lipids, current body weight and central fat deposition.(13,28)  The presence of a 
persistent specific antistreptococcal antibody, evaluated in a limited number of screened subjects, 
was also associated with higher levels of proteinuria, with the effect amplified by concurrent 
overweight or obesity.(29) Lower birthweights, skin sores, scabies and PSGN are among early life 
determinants.  Presumably presence or establishment of an early nephron deficit sets the stage for 
further cascading nephron loss based on hyperperfusion/ hyperfiltration.(24) The notable female 
predominance in renal disease and renal failure in this and other remote Aboriginal settings(7,13) 
might be partly explained by the equal susceptibility of girls and boys to PSGN, the documented lower 
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birthweights in females,(30) their greater accrual of body fat as adults, and the lower nephron 
endowment in females generally as demonstrated through autopsy studies.(31,32)  
 
PSGN has been called a disease of transition. Previously these Aboriginal people lived in small 
groups, were nomadic and did not have permanent dwellings. Now they live in very crowded, poorly 
ventilated, poorly maintained, dirty houses, where scabies thrives and Group A streptococci spread 
easily. We cannot comment on the occurrence of PSGN prior to the observation period, but a 
community death register and, more recently, dialysis registries, suggest that renal failure has 
increased dramatically since the late 1970s. This, we propose, is fuelled in part by PSGN and 
infections related to crowding, poor hygiene and poor nutrition, while phenomena associated with 
lifestyle and health transition, and improved survival of low birthweight infants have also 
contributed.(30)  Against this background of precipitating factors, the possibility of a genetic 
contribution to disease susceptibility is also being explored.  
 
The frequency of PSGN in this era in a western country is astonishing. The elimination of scabies, the 
marker of the environment in which PSGN and other third world diseases flourish, must be a top 
priority in this and other remote communities. This is a matter of wholesale improvement across all 
sectors such as housing, nutrition and education.  Justification could be provided based on cost 
savings in renal replacement therapy alone. The imminent trialling of anti-streptococcal vaccine could 
be extended to renal outcomes, rather than the exclusive rheumatic heart disease endpoints for which 
it was developed.(33) Nonetheless, the virtual elimination of PSGN in westernized environments was 
achieved without such a vaccine, and no less should be expected for Aboriginal people.   
 
Methods 
 
A community-wide health screen was performed from 2004-2006 in a remote Australian Aboriginal 
community with high rates of renal and cardiovascular disease, on all volunteers age 5+ years.  
Assessments included urinary albumin concentrations and albumin/creatinine ratios (ACRs) on 
random urine samples. Medical records were reviewed for notation of episodes of acute PSGN in 
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their past.  Associations of albuminuria with histories of PSGN at least 5 years prior to screening were 
evaluated in people less than age 40 yr at screening.  
 
The first diagnosis of PSGN was extracted from review of the local clinic records.  A diagnosis 
was based on a compatible clinical picture, defined by urine abnormalities (essential), accompanied 
by edema and/or hypertension and/or compatible serologic changes, including  elevated levels of 
antistreptococcal antibodies and low levels of total hemolytic complement and/or C3.(4)  The date of 
diagnosis had also been noted in all but 5 cases.   
 
The earliest documentation of episodes of PSGN in clinic records of participants in the screen 
was in 1970, within a few years of the arrival of the first pediatrician in the Northern Territory, 
Dr Alan Walker.  We do not know if few episodes occurred earlier, or were not recognised or 
not  recorded.  To minimize failure of case ascertainment in early life we therefore restricted 
the analysis to people who were less than <40 years of age at time of screening.  That age cut 
off also minimises bias created by premature mortality in this community, where the median 
age of adult death is about 47 years, and where, as we have shown,  albuminuria predicts all 
the causal renal death and much of the non-renal natural death.(14)  Evaluation of the 
association of episodes of PSGN with chronic renal disease were confined to subjects whose most 
recent episode of PSGN had been at least 5 years prior to screening, to minimize lingering 
contributions of still-recovering acute PSGN episodes to potential urine or renal functional 
abnormalities. This requirement necessarily excluded the five people with PSGN without a recorded 
date of diagnosis, and most of the children with a PSGN history who were age 5-9 years old at 
screening; thus the youngest age group was likewise not included in subsequent analyses.   
 
Descriptive statistics are presented as means, standard deviations and ranges, or as 
geometric means and 95% confidence intervals for continuous variables as appropriate, or as 
percentages and 95% confidence intervals for categorical variables. Comparisons by PSGN 
status were made using t-tests or Wilcoxon rank sums tests for continuous variables and by 
chi-squared test or Fisher exact test for categorical variables as appropriate.  Logistic 
regression was used to determine the association between a history of remote PSGN and specific 
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renal parameters with separate models developed for each sex.  All statistical tests were two tailed 
and the threshold of statistical significance was p<0.05. Analyses were performed using Stata version 
11.1 statistical software.(34) 
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Titles and legends: 
 
Table 1.   Distribution of people with a history of PSGN, by age and sex 
Table 2.  Descriptive statistics for people with a remote history of PSGN (> 5 yr prior) 
Table 3.  Characteristics of subjects by a remote history of PSGN (> 5 years prior) by sex.  
Mean (SD) except where otherwise specified. All p values reported are adjusted for age. 
Table 4   Renal parameters by a remote history of PSGN (>5 years prior) by sex and age group 
(number of participants in italics). 
Table 5. Odds Ratios (95%CI) for renal parameters by history of remote PSGN (> 5 years prior)                      
in people age 10-39 years at screening. Referrent group: people without a history of PSGN. 
 
Figure 1.  Episodes of PSGN since 1970 by year of occurrence. 
Figure 2. ACR levels by sex and age group according to a remote history of PSGN (> 5 years prior) 
Figure 3. ACR levels by sex and age group according to a remote history of PSGN  ( >5 year prior) 
Figure 4. ACR categories by sex and age group according to a remote history of PSGN (>5 years 
prior) 
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Tables 
 
Table 1.    
 
Age group Males Females 
5-9 yr 9/70 (12.9%) 4/79 (5.1%) 
10-19 yr 23/170 (13.5%) 21/141 (14.9%) 
20-29 yr 35/220 (15.9%) 37/139 (26.2%) 
30-39 yr 38/176 (21.6%) 34/145 (23.4%) 
40+ yr 9/174 (5.2%) 5/205 (2.4%) 
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Table 2.   
 
Males 
Age 
group 
PSGN: 
 n  
Age at PSGN (yrs): 
Mean (SD), range 
Time since PSGN (yrs): 
Mean(SD), range 
10-19 yr 20 5.1 (2.9), 0.9-10.5 11.7 (4.2), 5.3-18.7 
20-29 yr 35 6.7 (3.8), 2.2-22.3 17.9 (4.0), 7.3-24.8 
30-39 yr 37 10.0 (4.1), 0.3-22.3 24.2 (3.1), 11.7-35.0 
Females 
Age 
group 
PSGN: 
 n  
Age at PSGN (yrs): 
Mean (SD), range 
Time since PSGN (yrs): 
Mean (SD), range 
10-19 yr 16 4.9 (2.8),1.3-11.3 10.7 (2.9), 5.4-16.6 
20-29 yr 36 7.2 (3.8), 0.02-15.4 18.3 (4.4), 10.8-29.0 
30-39 yr 33 11.5 (6.7), 5.1-33.8 22.4 (6.2), 5.6-32.2 
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Table 3.   
 
  
Males 
Non PSGN 
N=465 
PSGN 
N=92 P 
Age (yrs) 24.7 (8.6) 27.6 (7.2) 0.02 
BMI (kg/m2) 21.4 (5.0) 21.0 (3.8) 0.14 
SBP (mmHg) 116.8 (15.2) 117 (14.0) 0.55 
DBP (mmHg) 72.1 (11.7) 72.2 (11.4) 0.28 
S Creatinine (µmol/L) 1 81.4 (19.0) 82.1 (12.3) 0.93 
HDL (mmol/L)2 1.3 (0.3) 1.3 (0.3) 0.12 
LDL (mmol/L)2 2.7 (0.8) 2.4 (0.9) 0.02 
Trigs (mmol/L)2 1.6 (1.2) 1.8 (1.7) 0.11 
CRP (mg/L)2 6.8 (11.3) 5.5 (5.3) 0.30 
HbA1c (%)2 5.7 (0.5) 5.7 (0.5) 0.98 
Diabetes3 3.4 (2.0,5.5) 7.6 (3.1-15.1) 0.24 
Proteinuria  >1+ 3 20.2 (16.7-24.2) 27.2 (18.4-37.4) 0.31 
Hematuria  >small3 7.1 (4.9-9.8) 13.0 (6.9-21.7) 0.04 
uACR (mg/mmol) 4 1.50 (1.3-1.7) 2.95 (2.1-4.2) 0.002 
ACR3     <3.4 80 (76.1-83.6) 57.6 (46.9-67.9) 0.001 
 3.4-33 16.5 (13.3-20.2) 30.4 (21.3-40.9)   
     34+ 3.4 (2.0-5.5) 12 (6.1-20.4)   
    
Females  
 Non PSGN 
N=325       
PSGN 
N=85 P 
Age (yrs) 24.5 (8.9) 27.2 (6.8) 0.01 
BMI (kg/m2) 22.9 (6.5) 24.3 (6.3) 0.59 
SBP (mmHg) 110.9 (13.3) 112.4 (14.1) 0.81 
DBP (mmHg) 71 (10.7) 72 (10.3) 0.88 
S Creatinine (µmol/L) 1 56.6 (9.7) 61.2 (24.5) 0.01 
HDL (mmol/L)2 1.3 (0.3) 1.3 (0.4) 0.82 
LDL (mmol/L)2 2.4 (0.7) 2.4 (0.8) 0.74 
Trigs (mmol/L)2 1.6 (1.4) 1.9 (1.6) 0.20 
CRP (mg/L)2 9.2 (9.8) 9.4 (10.2) 0.88 
HbA1c (%)2 6.0 (1.1) 6.1 (1.3) 0.66 
Diabetes3 11.1 (7.9-15.0) 15.3 (8.4-24.7) 0.85 
Proteinuria  >1+3 18.0 (14.1-22.8) 32.9 (23.1-44.0) 0.02 
Hematuria > small3 11.5 (8.1-15.3) 18.8 (11.2-28.8) 0.07 
uACR (mg/mmol) 4 2.8 (2.4-3.3) 6.5 (4.2-10.1) 0.005 
ACR3     <3.4 66.3 (60.8-71.4) 43.5 (32.8-54.7) 0.002 
 3.4-33 25.2 (20.5-30.2) 34.1 (24.2-45.2)   
      34+  8.6 (5.8-12.2) 22.4 (14.0-32.7)   
 
1 Males: n = 398 non-PSGN, 87 PSGN; Females: n = 266 non-PSGN, 83 PSGN 
2 Males: a minimum of 397 non-PSGN and 83 PSGN;  
  Females: a minimum of 258 non-PSGN and 79 PSGN 
3 % (95% CI)     
4 gmean, (95% CI) 
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Table 4.    
 
 
Males: 
 Urine ACR1 eGFR (MDRD)2 eGFR<603 
Age No PSGN PSGN No PSGN PSGN No PSGN PSGN 
10-19 yr 1.0 (0.9-1.1) 1.3 (0.7-2.4) 147.0 (46.7) 130.1 (21.8) 0 (0-4.2)* 0 (0-20)* 
 146 20 85 17 85 17 
20-29 yr 1.1 (1.0-1.3) 2.9 (1.6-5.2) 105.5 (16.2) 106.0 (19.6) 0 (0-2.0)* 0 (0-10)* 
 182 35 179 34 179 34 
30-39 yr 3.4 (2.6-4.5) 4.7 (2.7-8.2) 99.4 (19.8) 98.3 (15.1) 1.5 (0.2-5.3) 0 (0-10)* 
 138 37 134 36 134 36 
       
Females: 
 Urine ACR1 eGFR (MDRD)2 eGFR<603 
Age No PSGN PSGN No PSGN PSGN No PSGN PSGN 
10-19 yr 1.5 (1.3-1.8) 2.2 (0.9-5.5) 146.8 (30.9) 137.3 (24.2) 0 (0-6.2)* 0 (0-23.2)* 
 117 16 58 14 58 14 
20-29 yr 2.3 (1.8-2.9) 4.9 (2.5-9.5) 125.6 (24.9) 125.0 (27.1) 0 (0-3.7)* 0 (0-10)* 
 99 36 99 36 99 36 
30-39 yr 6.4 (4.6-8.8) 14.8 (7.2-30) 110.8 (21.9) 106.8 (33.0) 0 (0-3.2)* 12.1 (3-28) 
 110 33 109 33 109 33 
       
 
1 urine ACR: gm/mol, geometric mean (CI);  
2 eGFR,  arithmetic mean (SD) 
3 eGFR < 60, percent (CI),  
*one-sided, 97.5% CI 
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Table 5.  
 
 
 Renal outcome 
Males ACR > 3.4 ACR >34 
Adjusted for age  2.88 (1.7-4.8) 3.52 (1.5-8.0) 
Adjusted for age, BMI,  
SBP, DBP, diabetes 
3.22 (1.9-5.6) 4.96 (1.9-12.6) 
 Renal outcome 
Females ACR > 3.4 ACR >34 
Adjusted for age   2.26 (1.4-3.8) 2.86 (1.5-5.6) 
Adjusted for age, BMI,  
SBP, DBP, diabetes 
2.38 (1.4-4.1) 3.33 (1.6-7.0) 
   
 
  Figure 1. Episodes of PSGN since 1970 by year of occurrence. 
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Figure 2.  ACR levels by sex and age group according to a remote history of PSGN (> 5 years prior) 
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Figure 3.  ACR levels by sex and age group according to a remote history of PSGN (>5 year prior) 
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Figure 4. ACR categories by sex and age group according to a remote history of PSGN (>5 years prior) 
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